DVAX - Dynavax Technologies Corporation

https://www.dynavax.com

Hold Momentum: Bearish

Recent News

Dynavax Technologies ( DVAX ) Q2 Earnings and Revenues Beat Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.11

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bullish

Dynavax Technologies ( DVAX ) Upgraded to Buy: Here's Why

Zacks Commentary • 4 months ago • score: 0.31

Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.

52W High

$14.63

52W Low

$9.22

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.24

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

29.24

EV/EBITDA (<8 favorable)

30.92

EV/Revenue (<3 favorable)

2.69

P/S (TTM) (<3 favorable)

3.73

P/B (<3 favorable)

2.39

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.60%

Institutions (25–75% balanced)

97.90%

Shares Outstanding

117,267,000

Float

100,973,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

316,268,000

Gross Profit (TTM)

202,887,000

EPS (TTM)

-0.45

Profit Margin (>10% good)

-0.17%

Operating Margin (TTM) (higher better)

0.17%

ROE (TTM) (>15% strong)

-0.09%

EPS YoY (Quarterly) (>10% good)

0.76

Revenue YoY (Quarterly) (>8% good)

0.29

Momentum

Bearish momentum

Value

-0.2375

-0.2363

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025